{
    "nct_id": "NCT06650579",
    "official_title": "Randomized Controlled Trial of Leuprolide Plus Abiraterone Acetate (AA) Versus Relugolix Plus AA for Advanced Prostate Cancer: the REVELUTION-2 Trial",
    "inclusion_criteria": "* Men â‰¥ 18 years old\n* Non-metastatic prostate cancer\n* Non-metastatic, biochemically recurrent prostate cancer\n* Plan to undergo curative-intent pelvic radiation therapy (photons or protons) with or without brachytherapy\n* Plan to undergo up to 24 months of combination androgen deprivation therapy (ADT) plus AA and prednisone\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Metastatic prostate cancer requiring indefinitive ADT or chemotherapy\n* Prior exposure to androgen deprivation therapy\n* Prior exposure to chemotherapy, immunotherapy, or radiation therapy\n* History of cardiac bypass surgery or percutaneous coronary intervention\n* History of cardiac pacemaker or defibrillator",
    "miscellaneous_criteria": ""
}